Vass, Laurence D.
Lee, Sarah
Wilson, Frederick J.
Fisk, Marie
Cheriyan, Joseph
Wilkinson, Ian
Article History
Received: 2 July 2019
Accepted: 25 November 2019
First Online: 16 December 2019
Ethics approval and consent to participate
: The studies described in this work were conducted in accordance with Good Clinical Practice standards. The participating sites received a favourable ethical opinion from the local ethics committee and approval from the Administration of Radioactive Substances Advisory Committee. All participants provided informed written consent before enrolment in accordance with the Declaration of Helsinki.
: FJW is an employee and shareholder of GSK and previously a consultant to ECNP R &S, GlaxoSmithKline, IPPEC, King’s College London, Lundbeck A/S, Mentis Cura ehf and Pfizer Inc. and has received travel expenses as a guest speaker from Orion Pharma Ltd. IBW is funded by the British Heart Foundation and receives support from the Cambridge NIHR Comprehensive Biomedical Research Centre and Comprehensive Research Network. He has received grant support from GSK. JC is employed by Cambridge University Hospitals NHS Foundation Trust and obligated to spend 50% of his time on GSK clinical trial research via a secondment agreement, representing a significant relationship; however, he receives no benefits or compensation from GSK. JC acknowledges funding support from the Cambridge NIHR Comprehensive Biomedical Research Centre. LV is a PhD student funded by GSK (studentship agreement number: STU100043346/BIDS3000023795), MF declares that she has no competing interests. SL is a consultant to GSK and GE Heathcare.